J. Matthew Singleton

CIK: 0001243514

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (33.3%)

Position reduction

Option Exercises (M)2 (33.3%)

Derivative conversions

Awards (A)2 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

VKTX

Viking Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

VKTX
Viking Therapeutics, Inc.
Jan 2, 2026
Award(A)
Direct
3.2K shares-
VKTX
Viking Therapeutics, Inc.
Jan 2, 2025
Award(A)
Stock Option (Right to Buy)
Direct
18.8K shares-
VKTX
Viking Therapeutics, Inc.
Oct 25, 2024
Exercise(M)
Direct
16K shares at avg. $4.48$72K
VKTX
Viking Therapeutics, Inc.
Oct 25, 2024
Sale(S)
Direct
16K shares at avg. $79.50$1.3M
VKTX
Viking Therapeutics, Inc.
Sep 20, 2024
Exercise(M)
Direct
10.3K shares at avg. $1.19$12K
VKTX
Viking Therapeutics, Inc.
Sep 20, 2024
Sale(S)
Direct
10.3K shares at avg. $69.50$716K

		Type	Shares	Price		Ownership
Jan 2, 2026	VKTX Viking Therapeutics, Inc.	Award(A)	3,150	-	$0	Direct
Jan 2, 2025	VKTX Viking Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	18,800	-	-	Direct
Oct 25, 2024	VKTX Viking Therapeutics, Inc.	Exercise(M)	16,000	$4.48	$71,680	Direct
Oct 25, 2024	VKTX Viking Therapeutics, Inc.	Sale(S)	16,000	$79.50	$1,272,000	Direct
Sep 20, 2024	VKTX Viking Therapeutics, Inc.	Exercise(M)	10,300	$1.19	$12,257	Direct
Sep 20, 2024	VKTX Viking Therapeutics, Inc.	Sale(S)	10,300	$69.50	$715,850	Direct

1-6 of 6 transactions

About SINGLETON J MATTHEW

SINGLETON J MATTHEW (SEC CIK 0001243514) files insider reports with the SEC as Director of Viking Therapeutics, Inc. (VKTX).

Signal8 holds 4 ownership filings by SINGLETON J MATTHEW, all Form 4s, filed between Sep 20, 2024 and Jan 5, 2026. Those filings report 6 transactions, from Sep 20, 2024 to Jan 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on SINGLETON J MATTHEW's filings is in SAN DIEGO, CA.

Recent filings by SINGLETON J MATTHEW

Jan 2, 2026: Grant or award of VKTX shares (Form 4, code A).
Jan 2, 2025: Grant or award of VKTX derivative securities (Form 4, code A).
Oct 25, 2024: Option exercise of VKTX shares (Form 4, code M).
Oct 25, 2024: Open-market sale of VKTX shares (Form 4, code S).
Sep 20, 2024: Option exercise of VKTX shares (Form 4, code M).

Other insiders filing for Viking Therapeutics, Inc. (VKTX)

Kelly-Gemmell Dorothy Elizabeth, Director
Lian Brian, President & CEO
ZANTE GREG, Chief Financial Officer
Mancini Marianna, Chief Operating Officer
Chen Hubert C, Chief Medical Officer
Aubuchon Neil William, Chief Commercial Officer

How to read Form 4 transaction codes